Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.

Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

Rallybio (NASDAQ:RLYB) shares climbed ~114% in the premarket on Tuesday after the company announced an agreement to sell its ...

Investing.com -- Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock surged 11.5% while Rallybio Corp (NASDAQ: RLYB) shares jumped 35% Monday after Recursion acquired full rights to REV102, an oral ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and ...

Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

Rallybio Corp., a New Haven-based biotechnology company developing therapies for rare diseases, said Tuesday it has agreed to ...

Earlier this week, a prominent venture capitalist named Geoff Lewis — the managing partner of the multi-billion dollar investment firm Bedrock, which has backed high-profile tech companies including ...